[{"address1": "9708 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 243 1201", "fax": "301 738 2137", "website": "https://www.glycomimetics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Harout  Semerjian", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1126090, "exercisedValue": 0, "unexercisedValue": 465102}, {"maxAge": 1, "name": "Ms. Rachel K. King", "age": 64, "title": "Co-Founder & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian M. Hahn", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 822117, "exercisedValue": 0, "unexercisedValue": 98649}, {"maxAge": 1, "name": "Dr. Edwin  Rock M.D., Ph.D.", "age": 62, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 677399, "exercisedValue": 0, "unexercisedValue": 101250}, {"maxAge": 1, "name": "Ms. Stephanie R. Irish CPA", "age": 52, "title": "Vice President of Accounting", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian B. Dinneen-Long", "title": "General Counsel & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Johnson", "age": 55, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chinmaya  Rath", "age": 46, "title": "Senior VP & Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shantha  Tyavanagimatt Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.83, "open": 0.3536, "dayLow": 0.312, "dayHigh": 0.42, "regularMarketPreviousClose": 1.83, "regularMarketOpen": 0.3536, "regularMarketDayLow": 0.312, "regularMarketDayHigh": 0.42, "beta": 2.193, "forwardPE": -0.70111114, "volume": 40187653, "regularMarketVolume": 40187653, "averageVolume": 531336, "averageVolume10days": 1052370, "averageDailyVolume10Day": 1052370, "bid": 0.2952, "ask": 0.4034, "bidSize": 200, "askSize": 200, "marketCap": 20334100, "fiftyTwoWeekLow": 0.312, "fiftyTwoWeekHigh": 3.53, "priceToSalesTrailing12Months": 2033.41, "fiftyDayAverage": 2.5294, "twoHundredDayAverage": 2.0719, "currency": "USD", "enterpriseValue": -20650332, "floatShares": 40313071, "sharesOutstanding": 64450400, "sharesShort": 3012763, "sharesShortPriorMonth": 1490809, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0467, "heldPercentInsiders": 0.0308, "heldPercentInstitutions": 0.5313, "shortRatio": 5.84, "shortPercentOfFloat": 0.0674, "impliedSharesOutstanding": 373832992, "bookValue": 0.597, "priceToBook": 0.5284757, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -36899420, "trailingEps": -0.58, "forwardEps": -0.45, "enterpriseToRevenue": -2065.033, "enterpriseToEbitda": 0.528, "52WeekChange": 0.20394742, "SandP52WeekChange": 0.24486005, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "GLYC", "underlyingSymbol": "GLYC", "shortName": "GlycoMimetics, Inc.", "longName": "GlycoMimetics, Inc.", "firstTradeDateEpochUtc": 1389364200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "efe04473-e4ee-3464-8e89-48cc4b8490b8", "messageBoardId": "finmb_5703481", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.3155, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 7.0, "targetMedianPrice": 8.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 41792832, "totalCashPerShare": 0.648, "ebitda": -39121992, "totalDebt": 808402, "quickRatio": 6.14, "currentRatio": 6.407, "totalRevenue": 10000, "debtToEquity": 2.104, "returnOnAssets": -0.50546, "returnOnEquity": -0.90724, "freeCashflow": -21877018, "operatingCashflow": -34879904, "grossMargins": 1.0, "operatingMargins": -959.08344, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-07"}]